Abstract

Background: Parkinson's disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. Methods: Quantitative susceptibility mapping and R2* maps were obtained from 47 PD patients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) I, II, and III subscores, and levodopa-equivalent daily dosage. All studies were done while PD patients were "on drug." Results: Compared with controls, PD patients showed significantly increased susceptibility values in both right (cluster size=106mm3) and left (164mm3) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62mm3) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. Conclusion: The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.

Original languageEnglish (US)
Pages (from-to)317-324
Number of pages8
JournalMovement Disorders
Volume31
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Mesencephalon
Parkinson Disease
Iron
Levodopa
Magnetic Resonance Imaging
Red Nucleus
Iron Overload
Dopaminergic Neurons
Substantia Nigra
Biomarkers
Brain

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

@article{50f806c6354e4c3790979a57f818a01c,
title = "Quantitative susceptibility mapping of the midbrain in Parkinson's disease",
abstract = "Background: Parkinson's disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. Methods: Quantitative susceptibility mapping and R2* maps were obtained from 47 PD patients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) I, II, and III subscores, and levodopa-equivalent daily dosage. All studies were done while PD patients were {"}on drug.{"} Results: Compared with controls, PD patients showed significantly increased susceptibility values in both right (cluster size=106mm3) and left (164mm3) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62mm3) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. Conclusion: The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.",
author = "Guangwei Du and Tian Liu and Mechelle Lewis and Lan Kong and Yi Wang and James Connor and Richard Mailman and Xuemei Huang",
year = "2016",
month = "3",
day = "1",
doi = "10.1002/mds.26417",
language = "English (US)",
volume = "31",
pages = "317--324",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Quantitative susceptibility mapping of the midbrain in Parkinson's disease. / Du, Guangwei; Liu, Tian; Lewis, Mechelle; Kong, Lan; Wang, Yi; Connor, James; Mailman, Richard; Huang, Xuemei.

In: Movement Disorders, Vol. 31, No. 3, 01.03.2016, p. 317-324.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Quantitative susceptibility mapping of the midbrain in Parkinson's disease

AU - Du, Guangwei

AU - Liu, Tian

AU - Lewis, Mechelle

AU - Kong, Lan

AU - Wang, Yi

AU - Connor, James

AU - Mailman, Richard

AU - Huang, Xuemei

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Parkinson's disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. Methods: Quantitative susceptibility mapping and R2* maps were obtained from 47 PD patients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) I, II, and III subscores, and levodopa-equivalent daily dosage. All studies were done while PD patients were "on drug." Results: Compared with controls, PD patients showed significantly increased susceptibility values in both right (cluster size=106mm3) and left (164mm3) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62mm3) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. Conclusion: The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.

AB - Background: Parkinson's disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. Methods: Quantitative susceptibility mapping and R2* maps were obtained from 47 PD patients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) I, II, and III subscores, and levodopa-equivalent daily dosage. All studies were done while PD patients were "on drug." Results: Compared with controls, PD patients showed significantly increased susceptibility values in both right (cluster size=106mm3) and left (164mm3) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62mm3) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. Conclusion: The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.

UR - http://www.scopus.com/inward/record.url?scp=84941588274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941588274&partnerID=8YFLogxK

U2 - 10.1002/mds.26417

DO - 10.1002/mds.26417

M3 - Article

C2 - 26362242

AN - SCOPUS:84941588274

VL - 31

SP - 317

EP - 324

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 3

ER -